Lexaria Bioscience Corp. operates as a biotechnology company. It develops and out-licenses its patented drug delivery technology, DehydraTECH, which combines lipophilic molecules or active pharmaceutical ingredients with specific long-chain fatty acids and carrier compounds that improve the way they enter the bloodstream, increasing their effectiveness and allowing for lower overall dosing while promoting healthier oral ingestion methods. The company's DehydraTECH is used with a range of active molecules encompassing fat-soluble vitamins, pain medications, hormones, PDE5 inhibitors, antivirals, oral nicotine and its analogs, and cannabinoids. Its DehydraTECH technology evaluates therapeutic indications, including hypertension, heart disease, and diabetes; and is suitable for a variety of product formats, such as pharmaceuticals, nutraceuticals, over the counter, and consumer packaged goods. Lexaria Bioscience Corp. was incorporated in 2004 and is headquartered in Kelowna, Canada.
| 3.38 | |
| 3.1 | |
| - | |
| 3.41 | |
| 3.05 | |
| 0.8-6.85 | |
| 48 854 K | |
| 15 810 K | |
| 411 K | |
| -0.13 | |
| 1.023 |
No long-term obligations. The minimum period is one month only. No wait. You get an API key with instructions in a few seconds right after subscription.
Let me be clear: investing in biotech stocks isn’t for everyone. Investing in smaller biotech companies requires research, patience, and risk tolerance. Investing in A-rated biotech stocks offers hi...
NEW YORK, Nov. 01, 2023 (GLOBE NEWSWIRE) -- NetworkNewsAudio – Lexaria Bioscience Corp. (NASDAQ: LEXX) announces the availability of a broadcast titled, “Can Diabetes, Weight-Loss Drugs Get Eve...
Our 24/7 support would be happy to assist you via chat or email:
support@eodhistoricaldata.comVisit also:
